title: Invasiveness gene signature predicts a favorable outcome also in estrogen receptor-positive primary breast cancers treated with adjuvant tamoxifen.
authors.forename: Danila
authors.initials: D
authors.lastname: Coradini
authors.forename: Manuela
authors.initials: M
authors.lastname: Gariboldi
authors.forename: Maya
authors.initials: M
authors.lastname: Fedeli
authors.forename: Marco A
authors.initials: MA
authors.lastname: Pierotti
authors.forename: Maria Grazia
authors.initials: MG
authors.lastname: Daidone
mesh_terms: D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000473:pathology; D051927:CD24 Antigen / Q000032:analysis; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D018960:Hyaluronan Receptors / Q000032:analysis; D009361:Neoplasm Invasiveness; D011960:Receptors, Estrogen / Q000032:analysis*; D013629:Tamoxifen / Q000627:therapeutic use*
chemical_list: D051927:CD24 Antigen; C497889:CD24 protein, human; C497483:CD44 protein, human; D018960:Hyaluronan Receptors; D011960:Receptors, Estrogen; D013629:Tamoxifen